Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
India bonds gain as RBI FX inflows lift liquidity, spur short-term debt buying
MUMBAI: Indian government bonds rose in early trade on Thursday, led by the shorter-duration papers, after larger-than-expected dollar inflows under the central bank’s special schemes boosted rupee…
ICICI Bank narrows gap on HDFC Nifty lead
HDFC Bank is close to losing its position as the heaviest stock in the Nifty 50 to ICICI Bank after a sharp share-price decline narrowed the difference between the two lenders to less than half a…
TH mulls placing investment arm under SC oversight
Tabung Haji chairman says the framework is being fine-tuned to ensure that all key regulators are involved in its future regulatory structure.
Single-word dispute leaves G20 finance statement divided
A dispute over the term “non-market” lay at the centre of the breakdown between China and the United States at this week’s Group of 20 finance meeting, where Beijing withheld support for a consensus…
BoG Warns Public Against ‘Daily Wealth Guide’ Crypto Scam
The Bank of Ghana (BoG) and the Securities and Exchange Commission (SEC) have warned the public against a fraudulent crypto investment platform known as “Daily Wealth Guide,” which is allegedly…